Telomere Maintenance Mechanisms in Cancer: Clinical Implications

被引：65

作者：

Reddel, Roger R. ^{[1
,2
]}

机构：

[1] Childrens Med Res Inst, Westmead, NSW 2145, Australia

[2] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia

来源：

CURRENT PHARMACEUTICAL DESIGN | 2014年 / 20卷 / 41期

基金：

英国医学研究理事会;

关键词：

Alternative lengthening of telomeres; cancer; diagnosis; prognosis; telomerase; telomeres; therapy; TERT PROMOTER MUTATIONS; IMMORTAL HUMAN-CELLS; PROMYELOCYTIC LEUKEMIA BODIES; DNA-DAMAGE RESPONSE; HUMAN BREAST-CANCER; REVERSE-TRANSCRIPTASE; G-QUADRUPLEX; CLINICOPATHOLOGICAL PARAMETERS; HOMOLOGOUS RECOMBINATION; ALTERNATIVE MECHANISM;

D O I：

10.2174/1381612820666140630101047

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The presence of immortal cell populations with an up-regulated telomere maintenance mechanism (TMM) is an almost universal characteristic of cancers, whereas normal somatic cells are unable to prevent proliferation-associated telomere shortening and have a limited proliferative potential. TMMs and related aspects of telomere structure and function therefore appear to be ideal targets for the development of anticancer therapeutics. Such treatments would be targeted to a specific cancer-related molecular abnormality, and also be broad-spectrum in that they would be expected to be potentially applicable to most cancers. However, the telomere biology of normal and malignant human cells is a relatively young research field with large numbers of unanswered questions, so the optimal design of TMM-targeted therapeutic approaches remains unclear. This review outlines the opportunities and challenges presented by telomeres and TMMs for clinical management of cancer.

引用

页码：6361 / 6374

页数：14

共 50 条

[21] Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma [J].

Koneru, Balakrishna ;

Lopez, Gonzalo ;

Farooqi, Ahsan ;

Conkrite, Karina L. ;

Nguyen, Thinh H. ;

Macha, Shawn J. ;

Modi, Apexa ;

Rokita, Jo Lynne ;

Urias, Eduardo ;

Hindle, Ashly ;

Davidson, Heather ;

Mccoy, Kristyn ;

Nance, Jonas ;

Yazdani, Vanda ;

Irwin, Meredith S. ;

Yang, Shengping ;

Wheeler, David A. ;

Maris, John M. ;

Diskin, Sharon J. ;

Reynolds, C. Patrick .

CANCER RESEARCH, 2020, 80 (12) :2663-2675

[22] Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance [J].

Venturini, Lorenza ;

Daidone, Maria Grazia ;

Motta, Rosita ;

Cimino-Reale, Graziella ;

Hoare, Stacey F. ;

Gronchi, Alessandro ;

Folini, Marco ;

Keith, William Nicol ;

Zaffaroni, Nadia .

NEURO-ONCOLOGY, 2012, 14 (06) :736-744

[23] Evolution of telomere maintenance and tumour suppressor mechanisms across mammals [J].

Tian, Xiao ;

Doerig, Katherine ;

Park, Rosa ;

Qin, Alice Can Ran ;

Hwang, Chaewon ;

Neary, Alexander ;

Gilbert, Michael ;

Seluanov, Andrei ;

Gorbunova, Vera .

PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2018, 373 (1741)

[24] Telomere maintenance in African trypanosomes [J].

Li, Bibo .

FRONTIERS IN MOLECULAR BIOSCIENCES, 2023, 10

[25] T cell exhaustion in cancer: Mechanisms and clinical implications [J].

Wang, Jin-Cheng ;

Xu, Yong ;

Huang, Zheng-Ming ;

Lu, Xiao-Jie .

JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (06) :4279-4286

[26] Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies [J].

Gao, Jixuan ;

Pickett, Hilda A. .

NATURE REVIEWS CANCER, 2022, 22 (09) :515-532

[27] Integrated evaluation of telomerase activation and telomere maintenance across cancer cell lines [J].

Hu, Kevin ;

Ghandi, Mahmoud ;

Huang, Franklin W. .

ELIFE, 2021, 10

[28] Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications [J].

Matthews, P ;

Jones, CJ ;

Skinner, J ;

Haughton, M ;

de Micco, C ;

Wynford-Thomas, D .

JOURNAL OF PATHOLOGY, 2001, 194 (02) :183-193

[29] Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance [J].

Cerone, M. A. ;

Londono-Vallejo, J. A. ;

Autexier, C. .

ONCOGENE, 2006, 25 (56) :7411-7420

[30] Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance [J].

M A Cerone ;

J A Londoño-Vallejo ;

C Autexier .

Oncogene, 2006, 25 :7411-7420

← 1 2 3 4 5 →